Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Meta-analysis
100%
Chronic Obstructive Pulmonary Disease
100%
Pharmacotherapy
100%
Mixed Treatment Comparison
100%
Roflumilast
100%
Multiple Treatment Comparison
100%
Treatment Effect
66%
Severe Chronic Obstructive Pulmonary Disease
66%
Long-acting Bronchodilators
66%
Long-acting muscarinic Antagonist
66%
Comparative Analysis
33%
Randomized Clinical Trial
33%
Incidence Rate
33%
Therapeutic Implications
33%
Sensitivity Analysis
33%
Moderate to Severe
33%
Symptom Control
33%
Random Effects
33%
High Probability
33%
Relative Efficacy
33%
Drug Treatment
33%
Long-acting β2-agonist
33%
Combined Treatment
33%
Event Rate
33%
Phosphodiesterase 4 Inhibitor
33%
Drug Choice
33%
Point Estimate
33%
Acute Exacerbation of COPD (AECOPD)
33%
Current Guidelines
33%
Treatment Combination
33%
Chronic Obstructive Pulmonary Disease Treatment
33%
Rate Analysis
33%
Meta-analytic Approach
33%
Diseased Population
33%
Multinomial Analysis
33%
Mean Annual Frequency
33%
Treatment Lines
33%
Best First
33%
Medicine and Dentistry
Drug Therapy
100%
Meta-Analysis
100%
Chronic Obstructive Pulmonary Disease
100%
Roflumilast
60%
Bronchodilating Agent
40%
Muscarinic Antagonist
40%
Disease Exacerbation
20%
Treatment Effect
20%
Disease Management
20%
Systematic Review
20%
Phosphodiesterase IV Inhibitor
20%
Combination Drug Therapy
20%
Randomized Clinical Trials
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacotherapy
100%
Chronic Obstructive Lung Disease
100%
Roflumilast
60%
Muscarinic Receptor Blocking Agent
40%
Bronchodilating Agent
40%
Disease Exacerbation
20%
Randomized Clinical Trial
20%
Phosphodiesterase IV Inhibitor
20%
Relative Efficacy
20%